Liposomal Irinotecan (II) Fractionated Dosing Combined With 5-FU/LV (FOLFIRInali-3) and Bevacizumab in Second-line Treatment of Advanced Colorectal Cancer: A Single-arm, Phase II Clinical Study
Not Applicable
Recruiting
- Conditions
- Colorectal Cancer (CRC)
- First Posted Date
- 2025-07-02
- Last Posted Date
- 2025-07-02
- Target Recruit Count
- 46
- Registration Number
- NCT07047560
- Locations
- 🇨🇳
Tianjin Medical University Cancer Institute and Hospital, Tianjin, Tianjin, China
Chemoradiation Plus Iparomlimab Consolidation in Older With ESCC
Phase 2
Recruiting
- Conditions
- Esophageal Cancer
- Interventions
- First Posted Date
- 2025-06-26
- Last Posted Date
- 2025-06-26
- Target Recruit Count
- 52
- Registration Number
- NCT07038629
- Locations
- 🇨🇳
Tianjin Cancer Hospital, Tianjin, Tianjin, China
A Real-world Clinical Study of T-DXd for the Treatment of Chinese Patients With HER2 Overexpressing and HER2 Underexpressing Advanced Breast Cancer
Not yet recruiting
- Conditions
- HER2 OverexpressionAdvanced Stage Breast CancerLow Expression of HER2
- Interventions
- Drug: T-DXd (DS8201) 5.4 mg/kg, IVD, 1 cycle every 21 days.
- First Posted Date
- 2025-06-25
- Last Posted Date
- 2025-06-25
- Target Recruit Count
- 200
- Registration Number
- NCT07035353
Evaluation of the Efficacy and Safety of Adebrelimab Combined With SOX as Adjuvant Therapy for IIIB and IIIC Gastric Cancer
Phase 2
Not yet recruiting
- Conditions
- Gastric Cance
- Interventions
- Drug: Adebrelimab+SOX
- First Posted Date
- 2025-06-24
- Last Posted Date
- 2025-06-24
- Target Recruit Count
- 40
- Registration Number
- NCT07033143
A Multicenter, Single-Arm, Open-Label, Phase II Trial of Mosunetuzumab in Combination With Tislelizumab for r/r FL
Phase 2
Not yet recruiting
- Conditions
- Relapsed/Refractory Follicular Lymphoma
- Interventions
- First Posted Date
- 2025-06-22
- Last Posted Date
- 2025-06-22
- Target Recruit Count
- 22
- Registration Number
- NCT07031700
Supermicrosurgical Lymphaticovenous Anastomosis for Prevention of Upper Limb Lymphedema
Not Applicable
Not yet recruiting
- Conditions
- Breast Cancer-Related LymphedemaLymphedemaBreast Cancer Invasive
- First Posted Date
- 2025-06-18
- Last Posted Date
- 2025-06-18
- Target Recruit Count
- 120
- Registration Number
- NCT07026292
A Study of the Effect of Real-time Pressure Controllers on Subjective and Objective Symptoms of Peripheral Neuropathy Induced by Albumin Paclitaxel
Not Applicable
Recruiting
- Conditions
- Real Time Pressure ControllerBreast CancerAlbumin PaclitaxelPeripheral Neuropathy
- First Posted Date
- 2025-06-13
- Last Posted Date
- 2025-06-13
- Target Recruit Count
- 118
- Registration Number
- NCT07019233
- Locations
- 🇨🇳
Tianjin Medical University Cancer Institute and Hospital, Tianjin, China
FOLFOX Combined With Durvalumab (MEDI4736), Bevacizumab, and Stereotactic Body Radiotherapy in Sequential Treatment of Potentially Resectable Locally Advanced Hepatocellular Carcinoma
Phase 2
Not yet recruiting
- Conditions
- Hepatocellular Carcinoma (HCC)
- Interventions
- First Posted Date
- 2025-06-10
- Last Posted Date
- 2025-06-10
- Target Recruit Count
- 30
- Registration Number
- NCT07012798
- Locations
- 🇨🇳
Tianjin Cancer Hospital Airport Hospital, Tianjin, Tianjin, China
BR Combined With OR in Treatment-naïve Marginal Zone Lymphoma
Phase 2
Not yet recruiting
- Conditions
- Marginal Zone Lymphomas
- Interventions
- Drug: BR+OR
- First Posted Date
- 2025-06-06
- Last Posted Date
- 2025-06-06
- Target Recruit Count
- 37
- Registration Number
- NCT07008053
- Locations
- 🇨🇳
Fujian Cancer Hospital, Fuzhou, Fujian, China
🇨🇳The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, China
🇨🇳Hunan Cancer Hospital, Changsha, Hunan, China
Clinical Study of QL1706 in Combination With Olaparib for the Treatment of Patients With Previously Treated Homologous Recombination Repair-Deficient Recurrent or Metastatic Triple-Negative Breast Cancer
Phase 2
Not yet recruiting
- Conditions
- Triple-Negative Breast Cancer (TNBC)
- Interventions
- Drug: QL1706 Plus Olaparib
- First Posted Date
- 2025-06-05
- Last Posted Date
- 2025-06-05
- Target Recruit Count
- 46
- Registration Number
- NCT07005583
- Locations
- 🇨🇳
Tianjin Medical University Cancer Institute and Hospital, Tianjin, China